Tumour Necrosis Factor -308 and -238 Promoter Polymorphisms Are Predictors of a Null Virological Response in the Treatment of Brazilian Hepatitis C Patients

Overview

Journal Mem Inst Oswaldo Cruz

Specialties Parasitology
Tropical Medicine

Date 2014 May 3

PMID 24789557

Citations 2

Authors

Tarciana Grandi

Claudia Maria Dornelles da Silva

Karine Medeiros Amaral

Paulo Dornelles Picon

Cintia Costi

Nicole Nascimento Da Fre

Marilu Fiegenbaum

Tatiana Schaffer Gregianini

Christian Niel

Maria Lucia Rosa Rossetti

Affiliations

Soon will be listed here.

Abstract

Certain host single nucleotide polymorphisms (SNPs) affect the likelihood of a sustained virological response (SVR) to treatment in subjects infected with hepatitis C virus (HCV). SNPs in the promoters of interleukin (IL)-10 (-1082 A/G, rs1800896), myxovirus resistance protein 1 (-123 C/A, rs17000900 and -88 G/T, rs2071430) and tumour necrosis factor (TNF) (-308 G/A, rs1800629 and -238 G/A, rs361525) genes and the outcome of PEGylated α-interferon plus ribavirin therapy were investigated. This analysis was performed in 114 Brazilian, HCV genotype 1-infected patients who had a SVR and in 85 non-responders and 64 relapsers. A significantly increased risk of having a null virological response was observed in patients carrying at least one A allele at positions -308 [odds ratios (OR) = 2.58, 95% confidence intervals (CI) = 1.44-4.63, p = 0.001] or -238 (OR = 7.33, 95% CI = 3.59-14.93, p < 0.001) in the TNF promoter. The risk of relapsing was also elevated (-308: OR = 2.87, 95% CI = 1.51-5.44, p = 0.001; -238: OR = 4.20, 95% CI = 1.93-9.10, p < 0.001). Multiple logistic regression of TNF diplotypes showed that patients with at least two copies of the A allele had an even higher risk of having a null virological response (OR = 16.43, 95% CI = 5.70-47.34, p < 0.001) or relapsing (OR = 6.71, 95% CI = 2.18-20.66, p = 0.001). No statistically significant association was found between the other SNPs under study and anti-HCV therapy response.

Citing Articles

Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression.

Dhaouadi T, Riahi A, Ben Abdallah T, Gorgi Y, Sfar I Int J Immunopathol Pharmacol. 2024; 38:3946320241240705.

PMID: 38520313 PMC: 10960981. DOI: 10.1177/03946320241240705.

Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype.

Danilau D, Litvinchuk D, Solovey N, Krasko O, Karpov I Clin Exp Hepatol. 2017; 3(1):16-22.

PMID: 28856285 PMC: 5497450. DOI: 10.5114/ceh.2017.65279.

References

Ollier W . Cytokine genes and disease susceptibility. Cytokine. 2004; 28(4-5):174-8. DOI: 10.1016/j.cyto.2004.07.014. View

Grandi T, da Silva C, Amaral K, Picon P, Costi C, Fre N . Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene. Mem Inst Oswaldo Cruz. 2013; 108(1):48-53. PMC: 3974310. DOI: 10.1590/s0074-02762013000100008. View

Persico M, Capasso M, Persico E, Masarone M, De Renzo A, Spano D . Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J Hepatol. 2006; 45(6):779-85. DOI: 10.1016/j.jhep.2006.07.026. View

Strader D, Wright T, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4):1147-71. DOI: 10.1002/hep.20119. View

Wu M, Huang S, Chang Y, Shun C, Chang M, Lin M . Tumor necrosis factor-alpha and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma. J Infect Dis. 2002; 185(1):106-9. DOI: 10.1086/324771. View

Romero-Gomez M, Eslam M, Ruiz A, Maraver M . Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int. 2011; 31(4):443-60. DOI: 10.1111/j.1478-3231.2011.02449.x. View

Pena S, Di Pietro G, Fuchshuber-Moraes M, Genro J, Hutz M, Kehdy F . The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One. 2011; 6(2):e17063. PMC: 3040205. DOI: 10.1371/journal.pone.0017063. View

Dai C, Chuang W, Chang W, Chen S, Lee L, Hsieh M . Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis. 2005; 193(1):98-101. DOI: 10.1086/498244. View

Dogra G, Chakravarti A, Kar P, Chawla Y . Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response. Hum Immunol. 2011; 72(10):935-9. DOI: 10.1016/j.humimm.2011.06.008. View

10.

Excoffier L, Laval G, Schneider S . Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online. 2009; 1:47-50. PMC: 2658868. View

11.

Rosen H, McHutchison J, Conrad A, Lentz J, Marousek G, Rose S . Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol. 2002; 97(3):714-20. DOI: 10.1111/j.1572-0241.2002.05552.x. View

12.

Hadziyannis S, Sette Jr H, Morgan T, Balan V, Diago M, Marcellin P . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5):346-55. DOI: 10.7326/0003-4819-140-5-200403020-00010. View

13.

Mangia A, Santoro R, Piattelli M, Pazienza V, Grifa G, Iacobellis A . IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine. 2003; 25(3):103-9. DOI: 10.1016/j.cyto.2003.10.005. View

14.

Napoli J, Bishop G, McGuinness P, Painter D, McCaughan G . Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology. 1996; 24(4):759-65. DOI: 10.1002/hep.510240402. View

15.

Barrett S, Collins M, Kenny C, Ryan E, Keane C, Crowe J . Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol. 2003; 71(2):212-8. DOI: 10.1002/jmv.10472. View

16.

Knapp S, Hennig B, Frodsham A, Zhang L, Hellier S, Wright M . Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics. 2003; 55(6):362-9. DOI: 10.1007/s00251-003-0594-5. View

17.

Hijikata M, Mishiro S, Miyamoto C, Furuichi Y, Hashimoto M, Ohta Y . Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro. Intervirology. 2002; 44(6):379-82. DOI: 10.1159/000050075. View

18.

Larrea E, Garcia N, Qian C, Civeira M, Prieto J . Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology. 1996; 23(2):210-7. PMC: 7165845. DOI: 10.1002/hep.510230203. View

19.

Alves-Silva J, da Silva Santos M, Guimaraes P, Ferreira A, Bandelt H, Pena S . The ancestry of Brazilian mtDNA lineages. Am J Hum Genet. 2000; 67(2):444-61. PMC: 1287189. DOI: 10.1086/303004. View

20.

Thio C . Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis. 2008; 12(3):713-26, xi. PMC: 2597299. DOI: 10.1016/j.cld.2008.03.002. View